Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

The 2-drug immunotherapy combination of teclistamab-cqyv (Tecvayli) and talquetamab-tgvs (Talvey), both from Johnson & Johnson, reduced the risk of disease progression or death by 89% and cut the risk of death by 62% compared with standard-of-care regimens in patients with relapsed or refractory multiple myeloma (RRMM) who had received earlier lines of therapy, according to topline phase 3 trial results.¹ The data from the MonumenTAL-6 trial (NCT06208150) mark the lowest hazard ratio reported to date for any phase 3 bispecific antibody study in this disease setting.¹

The findings add fresh momentum to the debate over how, and when, dual-targeting immunotherapies should be sequenced against chimeric antigen receptor (CAR) T-cell therapy in earlier lines of RRMM care, a question with direct implications for treatment access, site-of-care planning, and cost management across health systems.

What Did the MonumenTAL-6 Trial Find?

MonumenTAL-6 is a 3-arm, global, randomized study evaluating teclistamab, a B-cell maturation antigen–directed CD3 T-cell engager plus talquetamab, a G protein–coupled receptor class C group 5 member D–directed CD3 T-cell engager, and talquetamab plus pomalidomide, against investigator’s choice of 2 standard combination regimens: elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).^1,2 Enrolled patients had received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide.

Both investigational arms met the primary end point of progression-free survival (PFS).¹ The teclistamab-talquetamab combination reduced the risk of progression or death by 89% (HR, 0.11; 95% CI, 0.08-0.16; P < .0001), while talquetamab plus pomalidomide reduced that risk by 73% (HR, 0.27; 95% CI, 0.2-0.35). An independent data monitoring committee recommended unblinding the study after the first interim analysis given the strength of the results.

How Does This Compare With Existing Myeloma Therapies?

Previously released data on teclistamab monotherapy in the phase 3 MajesTEC-9 trial (NCT05572515) demonstrated a 71% reduction in progression or death and a 40% overall survival benefit in a similar CD38-exposed population.³ The new MonumenTAL-6 combination data appear to exceed the MajesTEC-9 numbers, although cross-trial comparisons carry important caveats.

MonumenTAL-6 also differs meaningfully from the phase 3 MajesTEC-3 trial that recently supported teclistamab’s approval in combination with daratumumab: while MajesTEC-3 mainly enrolled patients who had not previously received an anti-CD38 antibody in the first-line setting, MonumenTAL-6 enrolled a CD38-exposed population, including roughly 80% of patients refractory to daratumumab.¹ That distinction matters for managed care stakeholders evaluating where each regimen fits in the treatment sequence, since a more heavily pretreated, antibody-refractory population represents a different clinical and reimbursement scenario than a CD38-naive one.

What Are the Practice and Access Implications?

Despite the outsized efficacy signal, J&J’s global oncology therapeutic area head, Yusri Elsayed, MD, PhD, has indicated the teclistamab-talquetamab combination is likely to be reserved for a narrower patient subset—potentially those at high risk of progression treated at large academic centers—rather than displacing chimeric antigen receptor (CAR) T-cell therapy broadly. Elsayed said he expects only a “very, very small percentage of patients” to be candidates for the doublet, with most earlier-line patients instead routed to daratumumab-teclistamab or ciltacabtagene autoleucel.⁴ Combining 2 bispecific mechanisms up front could also limit a later salvage option, since GPRC5D-directed therapy has shown utility following progression on BCMA-directed treatment.

This tension echoes previous thinking that myeloma sequencing decisions must weigh preserving future treatment options against maximizing up front efficacy, particularly as bispecific and CAR T-cell options multiply.⁵ Structural barriers—including infrastructure for managing cytokine release syndrome and neurologic toxicity, and disparities in access to specialized centers—have also been flagged as ongoing concerns for CAR T-cell and bispecific therapies alike.⁶

Full results from MonumenTAL-6 are expected to be presented at a future medical meeting and submitted to global health authorities. For managed care stakeholders, the data reinforce that sequencing strategy, site-of-care capacity, and long-term cost comparisons—rather than efficacy alone—will likely determine how broadly this combination is adopted.

References

1. Tecvayli + Talvey reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma. News release. Johnson & Johnson. July 23, 2026. Accessed July 31, 2026. https://www.prnewswire.com/news-releases/tecvayli--talvey-reduced-the-risk-of-disease-progression-or-death-by-89-and-the-risk-of-death-by-62-in-earlier-line-relapsedrefractory-multiple-myeloma-302833309.html
2. A study comparing talquetamab plus pomalidomide, talquetamab plus teclistamab, and elotuzumab, pomalidomide, and dexamethasone or pomalidomide, bortezomib, and dexamethasone in participants with relapsed or refractory myeloma who have received an anti-CD38 antibody and lenalidomide (MonumenTAL-6). ClinicalTrials.gov. Updated July 30, 2026. Accessed July 31, 2026. https://clinicaltrials.gov/study/NCT06208150
3. Shaw ML. MajesTEC-9 data add to accolades for teclistamab in multiple myeloma. AJMC^®. January 15, 2026. Accessed July 31, 2026. https://www.ajmc.com/view/majestec-9-data-add-to-accolades-for-teclistamab-in-multiple-myeloma
4. Liu A. J&J’s bispecific combo slashes myeloma progression risk by 89% in phase 3 trial. Fierce Pharma. July 23, 2026. Accessed July 31, 2026. https://www.fiercepharma.com/pharma/jj-bispecific-combo-slashes-myeloma-progression-risk-89-phase-3-trial
5. McCrear S. Phoenix IVBM spotlights oncology innovation, access barriers, and partnerships. AJMC. April 30, 2026. Accessed July 31, 2026. https://www.ajmc.com/view/phoenix-ivbm-spotlights-oncology-innovation-access-barriers-and-partnerships
6. Structural barriers may limit CAR T-cell therapy access in myeloma. AJMC. March 17, 2026. Accessed July 31, 2026. https://www.ajmc.com/view/structural-barriers-may-limit-car-t-cell-therapy-access-in-myeloma